Journal of Medicinal Chemistry · 2007 · 91 citations · 32 references
MedicinePharmacokineticsPharmacologyMolecular ImagingOrganometallic ChemistryStructural BiologyCoordination ChemistryLigand BindingPeptide ChemistryPositron Emission TomographyRadiopharmaceutical DesignTargeted Imaging AgentsCoordination GeometryCopper-64 LabelingCopper-64 RadiopharmaceuticalsIn Vivo StudiesOctahedral CoordinationPeptide-based Imaging AgentsPeptide-based ProbesPet Radiopharmaceuticals
Copper-64, a positron emitter suitable for positron emission tomography (PET), demonstrates improved in vivo clearance when chelated by the cross-bridged tetraazamacrocycle CB-TE2A compared to TETA. Good in vivo clearance was also observed for 64Cu-CB-TE2A conjugated to a peptide, which converts one coordinating carboxylate pendant arm to an amide. To better understand the in vivo stability of peptide- conjugated CB-TE2A, cross-bridged monoamides were synthesized. Crystal structures of natCu(II)-CB-TEAMA and natCu(II)-CB-PhTEAMA revealed hexadentate, distorted octahedral coordination geometry. In vivo biodistribution showed clearance of all 64Cu-radiolabeled cross-bridged monoamides from liver and bone marrow such that uptake at 24 h was <10% of uptake at 30 min. In contrast, >60% of 30 min uptake from 64Cu-TETA was retained in these tissues at 24 h. Clearance of 64Cu-cross-bridged monoamides from nontarget organs suggests good in vivo stability, thus supporting the use of CB-TE2A as a bifunctional chelator without modifications to the macrocycle backbone.
32
64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Carolyn J. Anderson, Farrokh Dehdashti, Paul Cutler et al. · PubMed · 2001 · 275 citations
Medicine, Nuclear Medicine, Oncology +17